The Trials Acceleration Programme (TAP)

In January 2020, Cure Leukaemia made a three-year commitment of £3,000,000 to fund the national Trials Acceleration Programme (TAP). This network consists of specialist research nurses at 12 blood cancer centres across the UK and a facilitatory Hub based at the Centre for Clinical Haematology at the Queen Elizabeth Hospital in Birmingham.

TAP enables the rapid setup and delivery of pioneering clinical trials for blood cancer connecting patients from a catchment area of over 20 million people with potentially life-saving options not currently available through standard care. Funding for research nurses to run TAP trials and studies has been granted to the following centres:

  1. Nottingham University Hospitals NHS Trust
  2. University College London Hospitals NHS Foundation Trust
  3. Queen Elizabeth Hospital Birmingham
  4. University Hospital of Wales, Cardiff
  5. The Christie NHS Foundation Trust, Manchester
  6. St James' University Hospital, Leeds
  7. University Hospital Southampton
  8. Sheffield Teaching Hospitals NHS Foundation Trust
  9. Guy’s & St Thomas’ NHS Foundation Trust, London
  10. John Radcliffe Hospital, University Hospitals Oxford NHS Trust 
  11. Belfast City Hospital
  12. Beatson West of Scotland Cancer Centre, Glasgow?

The successful centres were selected from 21 applications by an International Peer Review Panel, chaired by Professor Alessandro Rambaldi from the University of Milan, to receive dedicated specialist research nurse funding for the three-year period from 1st January 2020 to 31st December 2022. Grants of £50,000 per year will be paid to these institutions by Cure Leukaemia to support the employment of a research nurse who will work closely with the TAP Hub at the University of Birmingham to deliver practice informing trials in blood cancer.


Building on the successful track record of the TAP programme, previously solely funded by Blood Cancer UK from 2011-2019, patients, from a catchment region of 20 million people, will have access to the wave of new drug and cellular therapies which promise to transform the outcomes for patients with blood cancer.

Blood cancer remains the third biggest cancer killer in the UK with approximately 38,000 people diagnosed and 14,000 losing their lives to the disease every year. The funding will not only give blood cancer patients that have exhausted standard treatments for the disease hope through recruitment to pioneering new clinical trials, but also help continue global progress towards finding effective treatments for all forms of blood cancer.

Ideas for new clinical trials can be submitted by clinicians from anywhere in the United Kingdom to the TAP Hub in Birmingham for consideration by the independent TAP Steering Committee. All ideas should be sent to TAP Team Leader Sonia Fox for consideration: S.Fox.2@bham.ac.uk

The Impact of TAP

Mark Hill from London was diagnosed with blood disorder Polycythaemia Vera in 2004 and he the very first patient recruited to the MAJIC clinical trial made available thanks to the TAP which is now funded by Cure Leukaemia.

 
 

 

 

What we do

The Trials Acceleration Programme (TAP)

How funds raised for Cure Leukaemia help save lives

Cure Leukamia Pre footer image
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell